Re the major determinants of sequelae [14]. In this way, it may > 자유게시판

Re the major determinants of sequelae [14]. In this way, it may be questioned if an earlier immunosuppressive treatment in our patient #3 could have prevented the irreversible loss of brain parenchyma. In conclusion, physicians should consider ANCA dosage in patients presenting with otherwise unexplained SE or seizures, inflammatory changes at brain MRI, with or without other systemic signs or symptoms of AAV. Indeed, in this peculiar clinical setting, ANCA positivity may lead physicians to suspect an autoimmune aetiology and to promptly start adequate immunotherapy.Ferlazzo et al. BMC Neurology 2014, 14:148 http://www.biomedcentral.com/1471-2377/14/Page 5 ofConsentWritten informed consents were obtained from the patients #2,3 for publication of this case series and any accompanying images. Written informed consent was obtained from the wife of patient 1 for publication of this case series and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.Competing interests All authors declare that they have no competing interests. There is no funding or financial support. Authors' contributions EF: drafting/revising/critique the manuscript, study concept or design, collection of data. AG: revising/critique the manuscript, study concept or design, collection of data, supervision. MB: revising/critique the manuscript. SG: revising/critique the manuscript. LM: revising/critique the manuscript, collection of data. AL: revising/critique the manuscript, collection of data. VC: revising/critique the manuscript, collection of data. CR: revising/critique the manuscript, study concept or design, collection of data. UA: drafting/ revising/critique the manuscript, study concept or design, collection of data. All authors read and approved the final manuscript. Author details 1 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. 2Regional Epilepsy Centre, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy. 3Institute of Neurology, University Magna Graecia - Catanzaro, Italy. Received: 22 February 2014 Accepted: 11 July 2014 Published: 17 July 2014 References 1. Berden A, G eroglu A, Jayne D, Luqmani R, Rasmussen N, Bruijn JA, Bajema I: Diagnosis and management of ANCA associated vasculitis. BMJ 2012, 344:e26. 2. Miller KS, Miller JM: Wegener's granulomatosis presenting as a primary seizure disorder with brain lesions demonstrated by magnetic resonance imaging. Chest 1993, 103:316?18. 3. Weinberger LM, Cohen ML, Remler BF, Naheedy MH, Leigh RJ: Intracranial Wegener's granulomatosis. Neurology 1993, 43:1831?834. 4. Bajema IM, Hagen EC, Weverling-Rijnsburger AW, van der Pijl Capivasertib H, van Dorp WT, van Ravenswaay Claasen HH, Bruijn JA: Cerebral involvement in two patients with Wegener's granulomatosis. Clin Nephrol 1997, 47:401?06. 5. Nordmark G, Boquist L, R nblom L: Limited Wegener's granulomatosis with central nervous system involvement and fatal outcome. J Intern Med 1997, 242:433?36. 6. von Scheven E, Lee C, Berg BO: Pediatric Wegener's granulomatosis complicated by central nervous system vasculitis. Pediatr Neurol 1998, 19:317?319. 7. Ulinski T, Martin H, Mac Gregor B, Dardelin R, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/17139194 Cochat P: Fatal neurologic involvement in pediatric Wegener's granulomatosis. Pediatr Neurol 2005, 32:278?81. 8. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Segelmark M, Cohen-Tervaert JW, Scott D: Development and validation of a consensus methodology for th.